Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. Co.'s segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. Co. provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. The LAB stock yearly return is shown above.
The yearly return on the LAB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2025 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LAB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|